{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:22:25Z","timestamp":1787595745244,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022416","name":"Center for Drug Evaluation and Research","doi-asserted-by":"publisher","award":["U01-FD007763"],"award-info":[{"award-number":["U01-FD007763"]}],"id":[{"id":"10.13039\/100022416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM145304"],"award-info":[{"award-number":["T32GM145304"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014726","name":"National Institute for Innovation in Manufacturing Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014726","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijbiomac.2025.149062","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:14:04Z","timestamp":1763630044000},"page":"149062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P2","title":["Multimodal mass spectrometric characterization of structural microheterogeneity in rituximab reference and biosimilars"],"prefix":"10.1016","volume":"334","author":[{"given":"Youngseo","family":"Na","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill L.","family":"Kinzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Morrissette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Seok","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schwendeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.149062_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2021.11.009","article-title":"The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems","volume":"52","author":"Kvien","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ijbiomac.2025.149062_bb0010","series-title":"Biosimilar Product Information, Available at Biosimilar Product Information| FDA [Access at 19-12-2022]","author":"US Food and Drug Administration","year":"2020"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149062_bb0015","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1208\/s12248-016-9882-5","article-title":"Analytical similarity assessment in biosimilar studies","volume":"18","author":"Chow","year":"2016","journal-title":"AAPS J."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.149062_bb0020","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nrd3746","article-title":"Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars","volume":"11","author":"Berkowitz","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149062_bb0025","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1802135","article-title":"Antigen physiochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity","volume":"12","author":"Sun","year":"2020","journal-title":"Mabs"},{"key":"10.1016\/j.ijbiomac.2025.149062_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.929895","article-title":"Role of Fc Core Fucosylation in the effector function of IgG1 antibodies","volume":"13","author":"Golay","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.149062_bb0035","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0022-2836(02)01250-0","article-title":"Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity","volume":"325","author":"Krapp","year":"2003","journal-title":"J. Mol. Biol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149062_bb0040","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.bbagen.2005.10.002","article-title":"Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy","volume":"1760","author":"Yamaguchi","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"30","key":"10.1016\/j.ijbiomac.2025.149062_bb0045","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.149062_bb0050","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149062_bb0055","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.4049\/jimmunol.0903296","article-title":"Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR","volume":"184","author":"Suzuki","year":"2010","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149062_bb0060","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jps.24136","article-title":"Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation","volume":"104","author":"Gao","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.149062_bb0065","series-title":"Overview for Health Care Professionals","author":"US Food and Drug Administration","year":"2024"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.149062_bb0070","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40259-023-00631-4","article-title":"Do the outcomes of clinical efficacy trials matter in regulatory decision-making for biosimilars?","volume":"37","author":"Kirsch-Stefan","year":"2023","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149062_bb0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/NAN.0000000000000528","article-title":"Biosimilars: from production to patient","volume":"47","author":"Sheridan","year":"2024","journal-title":"J. Infus. Nurs."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149062_bb0080","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/biologics2020009","article-title":"The coming of age of biosimilars: a personal perspective","volume":"2","author":"Niazi","year":"2022","journal-title":"Biologics"},{"key":"10.1016\/j.ijbiomac.2025.149062_bb0085","series-title":"Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations Guidance for Industry, (Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research)","author":"US Food and Drug Administration","year":"2025"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.149062_bb0090","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-025-02168-y","article-title":"The tailored biosimilar approach: expectations and requirements","volume":"85","author":"Guillen","year":"2025","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149062_bb0095","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1042\/bst0250705","article-title":"Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin\u2019s B-cell lymphoma","volume":"25","author":"Anderson","year":"1997","journal-title":"Biochem. Soc. Trans."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149062_bb0100","first-page":"148","article-title":"Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin\u2019s lymphoma","volume":"35","author":"Dotan","year":"2010","journal-title":"P T"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.149062_bb0105","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3174\/ajnr.A2142","article-title":"Rituximab (Rituxan)","volume":"31","author":"Selewski","year":"2010","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.149062_bb0110","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.149062_bb0115","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40259-013-0036-3","article-title":"Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab","volume":"27","author":"Visser","year":"2013","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149062_bb0120","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/19420862.2018.1433976","article-title":"Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product","volume":"10","author":"Lee","year":"2018","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149062_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15887-z","article-title":"A homogeneous bioluminescent immunoassay for parallel characterization of binding between a panel of antibodies and a family of Fcgamma receptors","volume":"12","author":"Nath","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149062_bb0130","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/pro.45","article-title":"Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn","volume":"18","author":"Pan","year":"2009","journal-title":"Protein Sci."},{"issue":"17","key":"10.1016\/j.ijbiomac.2025.149062_bb0135","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1021\/acs.analchem.1c00960","article-title":"Determination of the rituximab binding site to the CD20 epitope using SPOT synthesis and surface plasmon resonance analyses","volume":"93","author":"Bar","year":"2021","journal-title":"Anal. Chem."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.149062_bb0140","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/glycob\/cwv065","article-title":"Fc glycans of therapeutic antibodies as critical quality attributes","volume":"25","author":"Reusch","year":"2015","journal-title":"Glycobiology"},{"key":"10.1016\/j.ijbiomac.2025.149062_bb0145","series-title":"Application Number: 761088Orig1s000. Product Quality Review(s)","author":"US Food and Drug Administration Center for Drug Evaluation and Research","year":"2019"},{"key":"10.1016\/j.ijbiomac.2025.149062_bb0150","series-title":"Application Number: 761103Orig1s000. Product Quality Review(s)","author":"US Food and Drug Administration Center for Drug Evaluation and Research","year":"2019"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149062_bb0155","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/glycob\/cwl057","article-title":"Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types","volume":"17","author":"Kanda","year":"2007","journal-title":"Glycobiology"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149062_bb0160","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.molimm.2013.10.005","article-title":"Comparison of the glycosylation of in vitro generated polyclonal human IgG and therapeutic immunoglobulins","volume":"57","author":"Ritamo","year":"2014","journal-title":"Mol. Immunol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.149062_bb0165","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.molimm.2006.09.005","article-title":"Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality","volume":"44","author":"Scallon","year":"2007","journal-title":"Mol. Immunol."},{"issue":"8\u20139","key":"10.1016\/j.ijbiomac.2025.149062_bb0170","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.molimm.2009.02.002","article-title":"Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors","volume":"46","author":"Bertolotti-Ciarlet","year":"2009","journal-title":"Mol. Immunol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149062_bb0175","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.coi.2008.06.007","article-title":"Terminal sugars of Fc glycans influence antibody effector functions of IgGs","volume":"20","author":"Raju","year":"2008","journal-title":"Curr. Opin. Immunol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.149062_bb0180","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1172\/JCI82695","article-title":"Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity","volume":"125","author":"Quast","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijbiomac.2025.149062_bb0185","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejpb.2019.12.003","article-title":"Multifaceted assessment of rituximab biosimilarity: the impact of glycan microheterogeneity on Fc function","volume":"146","author":"Kang","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149062_bb0190","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jasms.2008.11.011","article-title":"Mass spectrometry analysis of photo-induced methionine oxidation of a recombinant human monoclonal antibody","volume":"20","author":"Liu","year":"2009","journal-title":"J. Am. Soc. Mass Spectrom."},{"issue":"18","key":"10.1016\/j.ijbiomac.2025.149062_bb0195","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1021\/bi702238b","article-title":"Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation","volume":"47","author":"Liu","year":"2008","journal-title":"Biochemistry"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.149062_bb0200","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/19420862.2017.1368602","article-title":"Forced degradation of recombinant monoclonal antibodies: a practical guide","volume":"9","author":"Nowak","year":"2017","journal-title":"MAbs"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.149062_bb0205","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s11095-007-9241-4","article-title":"Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures","volume":"24","author":"Chu","year":"2007","journal-title":"Pharm. Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.149062_bb0210","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1016\/j.xphs.2019.07.019","article-title":"An automated and qualified platform method for site-specific succinimide and deamidation quantitation using low-pH peptide mapping","volume":"108","author":"Cao","year":"2019","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149062_bb0215","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4161\/mabs.24458","article-title":"Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule","volume":"5","author":"Ouellette","year":"2013","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149062_bb0220","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41598-019-57184-2","article-title":"Characterization of IgG1 Fc deamidation at asparagine 325 and its impact on antibody-dependent cell-mediated cytotoxicity and FcgammaRIIIa binding","volume":"10","author":"Lu","year":"2020","journal-title":"Sci. Rep."},{"issue":"18","key":"10.1016\/j.ijbiomac.2025.149062_bb0225","doi-asserted-by":"crossref","first-page":"6004","DOI":"10.1021\/ac050672d","article-title":"Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies","volume":"77","author":"Chelius","year":"2005","journal-title":"Anal. Chem."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.149062_bb0230","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/19420862.2018.1478646","article-title":"Structure based prediction of asparagine deamidation propensity in monoclonal antibodies","volume":"10","author":"Yan","year":"2018","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149062_bb0235","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1038\/s41598-021-85563-1","article-title":"Safety of switching between rituximab biosimilars in onco-hematology","volume":"11","author":"Urru","year":"2021","journal-title":"Sci. Rep."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025096199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025096199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:18:11Z","timestamp":1781176691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025096199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":47,"alternative-id":["S0141813025096199"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149062","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multimodal mass spectrometric characterization of structural microheterogeneity in rituximab reference and biosimilars","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"149062"}}